Registered title, quoted from ClinicalTrials.gov
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 5
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
- Study siteFirst Affiliated Hospital of Fujian Medical University福建医科大学附属第一医院FuzhouHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05698147, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically documented PCNSL and SCNSL secondary to histologically documented systemic diffuse large B-cell lymphoma (DLBCL).
Inclusion criterion 4
Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 28 days prior to cycle1 day 1(C1D1). For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells.
Inclusion criterion 8
Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3
Exclusion criterion 11
Patients must have response or remain stable disease for 2 months to prior methotrexate-based regimen.
Inclusion criterion 6
Patients with disease progression within 6 months of prior methotrexate-containing regimen.
Exclusion criterion 4
Patients have received chemotherapy, monoclonal antibodies or targeted anticancer therapy within 21 days or 5 half-lives, whichever is shorter, prior to C1D1.
Exclusion criterion 6
Participants must have an Eastern Cooperative Oncology Group performance status of 0-3.
Inclusion criterion 9
Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L
Inclusion criterion 11
Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days prior to study registration c Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
Inclusion criterion 12
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal.
Inclusion criterion 14
Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.
Inclusion criterion 15
Calculated creatinine clearance(CrCl)≥50ml/min using the Cockcroft-Gault equation or 24-hour urine collection.
Inclusion criterion 16
Known active hepatitis B, or C infection or HIV infection; Note: Hepatitis B virus (HBV) surface antigen (HBsAg) and or hepatitis B core antibody-positive but undetectable HBV DNA or Hepatitis C virus (HCV) antibody positive but hepatitis C virus RNA undetectable are allowed.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05698147, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
- Participants must be able to understand and be willing to sign a written informed consent document.
- Men and woman who are 18-75 years old on the day of consenting to the study.
- Histologically documented PCNSL and SCNSL secondary to histologically documented systemic diffuse large B-cell lymphoma (DLBCL).
- Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL.
- Patients must have response or remain stable disease for 2 months to prior methotrexate-based regimen.
- Patients who had prior autologous hematopoietic stem cell transplantation are eligible.
- Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 28 days prior to cycle1 day 1(C1D1). For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells.
- Participants must have an Eastern Cooperative Oncology Group performance status of 0-3.
- Participants must have adequate bone marrow and organ function shown by:
- Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L
- Platelets ≥ 75 x 10\^9/L and no platelet transfusion within the past 14 days prior to study registration c Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
- International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal.
- Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome.
- Calculated creatinine clearance(CrCl)≥50ml/min using the Cockcroft-Gault equation or 24-hour urine collection.
- Life expectancy of > 3 months.
Exclusion Criteria:
- Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded.
- Lymphoma patients with only intraocular involvement.
- Pathological diagnosis of PCNSL is T-cell lymphoma.
- Patients with disease progression within 6 months of prior methotrexate-containing regimen.
- patients only had received stereotactic radiation therapy as prior treatment.
- Patients have received chemotherapy, monoclonal antibodies or targeted anticancer therapy within 21 days or 5 half-lives, whichever is shorter, prior to C1D1.
- Patients with active, unstable cardiovascular diseases, fits any of the following:
- myocardial infarction within 6 months prior to the study enrollment
- unstable angina within 3 months prior to the study enrollment
- Uncontrolled clinically-significant conduction abnormalities (e.g., ventricular tachycardia, ventricular fibrillation, etc.)
- Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3
- Echocardiography showing left ventricular ejection fraction less than 50%
- Uncontrolled active infection within 1 week prior to the first dose of study drug.
- Known active hepatitis B, or C infection or HIV infection; Note: Hepatitis B virus (HBV) surface antigen (HBsAg) and or hepatitis B core antibody-positive but undetectable HBV DNA or Hepatitis C virus (HCV) antibody positive but hepatitis C virus RNA undetectable are allowed.
- Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
- Prior exposure to a selective inhibitor of nuclear export(SINE) compound, including selinexor.
- Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.
Quoted from ClinicalTrials.gov, NCT05698147, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05698147, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.